Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review.

IF 4.5 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2025-07-07 DOI:10.1093/ibd/izae220

Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera

{"title":"Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review.","authors":"Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera","doi":"10.1093/ibd/izae220","DOIUrl":null,"url":null,"abstract":"Background: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants.Methods: EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero.Results: A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination.Conclusions: Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1789-1796"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izae220","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants.

Methods: EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero.

Results: A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination.

Conclusions: Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.

查看原文本刊更多论文

宫内接触过生物制剂的婴儿接种轮状病毒疫苗的安全性：系统回顾。

背景：对于子宫内暴露于生物制剂的婴儿，胃肠病学社会指南建议在其 6-12 个月大之前或血清生物制剂水平检测不到之前不要接种轮状病毒活疫苗。我们进行了一项系统性综述，以评估暴露于生物制剂的婴儿接种轮状病毒疫苗的安全性：方法：我们检索了 EMBASE、PubMed、Scopus 和 Cochrane 数据库中从 2006 年到 2024 年有关抗肿瘤坏死因子（TNFs）（即英夫利昔单抗、阿达木单抗、戈利木单抗、certolizumab）和非 TNF 生物制剂（即维妥珠单抗、乌司替吉单抗、利赞珠单抗、米利珠单抗）暴露于子宫内的婴儿接种轮状病毒疫苗安全性的原始数据：通过数据库搜索获得了 7185 项筛选结果，其中有 10 项研究符合纳入标准。为暴露于生物制剂的婴儿接种轮状病毒疫苗的案例超过 300 例（n = 162 例暴露于抗肿瘤坏死因子，n = 142 例暴露于非抗肿瘤坏死因子生物制剂）。暴露于生物制剂的婴儿发生严重不良事件或与接种轮状病毒疫苗相关的任何严重程度的不良事件的风险均未增加：结论：对暴露于生物制剂的婴儿接种轮状病毒活疫苗似乎是安全的。因此，在对风险和益处进行仔细研究后，轮状病毒疫苗接种在这一人群中可能会发挥作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.